<p>Avalo Therapeutics, Inc.（纳斯达克代码：AVTX - 获取免费报告）在周四的交易中，股价出现异常强劲的交易量，此前 Citizens Jmp 将其目标股价从 52.00 美元上调至 62.00 美元。Citizens Jmp 目前对该股票的评级为市场表现优于大盘。在午盘交易中，约有 1,699,078 股成交，较前一交易日的 916,530 股交易量增加了 85%。该股最后交易价格为 22.55 美元，之前收盘价为 21.81 美元。</p>
<p>获取 <strong>Avalo Therapeutics</strong> 的提醒：</p>
<p>其他分析师也对该公司发布了报告。Guggenheim 在 2 月 2 日的研究报告中开始覆盖 Avalo Therapeutics。他们给予该公司 “买入” 评级，目标价为 50.00 美元。HC Wainwright 在 3 月 25 日的报告中将 Avalo Therapeutics 的目标价从 25.00 美元上调至 40.00 美元，并给予该股 “买入” 评级。花旗集团在周三的报告中重申了对 Avalo Therapeutics 的 “优于大盘” 评级。Weiss Ratings 在 4 月 8 日的研究报告中重申了对 Avalo Therapeutics 的 “卖出（d-）” 评级。最后，Wedbush 在周三的研究报告中将 Avalo Therapeutics 的目标价从 29.00 美元上调至 40.00 美元，并给予该股 “优于大盘” 评级。一位投资分析师对该股给予了强烈买入评级，九位给予了买入评级，一位对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 48.14 美元。</p>
<p><strong>查看我们关于 Avalo Therapeutics 的最新报告</strong></p>
<h2>内部人士下注</h2>
<p>在相关消息中，首席财务官 Christopher Ryan Sullivan 在 4 月 29 日的交易中出售了 8,458 股公司的股票。股票以平均价格 13.09 美元出售，总价值为 110,715.22 美元。交易完成后，首席财务官直接持有 8,880 股公司的股票，价值约为 116,239.20 美元。这代表其持股比例减少了 48.78%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Mittie Doyle 在 3 月 16 日的交易中出售了 25,492 股公司的股票。该股票以平均价格 16.15 美元出售，总价值为 411,695.80 美元。交易完成后，该内部人士直接持有 3,622 股公司的股票，价值约为 58,495.30 美元。这笔交易代表其持股比例减少了 87.56%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 63,015 股公司股票，价值 987,326 美元。公司内部人士持有公司股票的 4.46%。</p>
<h2>影响 Avalo Therapeutics 的关键头条</h2>
<p>以下是本周影响 Avalo Therapeutics 的关键新闻：</p>
<ul>
<li>积极情绪：积极的第二阶段 LOTUS 顶线结果——LOTUS 试验在两个剂量下均达到了主要终点（第 16 周的 HiSCR75），并在关键次要终点上显示出益处；Avalo 表示将推进 abdakibart 进入注册性第三阶段项目，这大大降低了项目风险，并支持更高的长期商业潜力。阅读更多。</li>
<li>积极情绪：大型 3.75 亿美元的公开发行定价以资助开发——Avalo 以 17.75 美元的价格定价约 1973 万股（加上预先融资的认股权证），以筹集约 3.75 亿美元的总收益；管理层表示收益将支持 abdakibart 的第三阶段和一般公司用途，增强公司的现金流。阅读更多。</li>
<li>积极情绪：分析师升级和更高目标——几家公司提高了评级/目标（例如：BTIG 至 58 美元，Citizens JMP 至 62 美元，Wedbush 至 40 美元），反映出数据发布后的乐观情绪，并可能促进购买兴趣。阅读更多。</li>
<li>中性情绪：市场反应/交易时机——该发行预计将在符合惯例条件的情况下完成（预计在 5 月 7 日），承销商有 30 天的选择权购买额外股票；短期交易将反映数据和最终关闭细节。阅读更多。</li>
<li>消极情绪：稀释和潜在的短期卖压——大规模的股权融资将稀释现有股东的股份，并可能限制股票价格，直到收益被使用和第三阶段里程碑达成。阅读更多。</li>
<li>消极情绪：对冲/内部人士活动的迹象——报告显示异常大的看跌期权活动和最近的内部人士出售（多位高管出售股票），投资者可能将其解读为短期对冲或税务/流动性出售，并作为短期波动的警示指标。</li>
</ul>
<h2>机构投资者对 Avalo Therapeutics 的看法</h2>
<p>几家对冲基金最近买卖了该公司的股票。Geode Capital Management LLC 在第二季度将其在 Avalo Therapeutics 的持股增加了 2.5%。Geode Capital Management LLC 目前拥有 110,460 股该公司的股票，价值 552,000 美元，此前在上个季度又购买了 2,648 股。Nantahala Capital Management LLC 在第二季度将其在 Avalo Therapeutics 的持股增加了 10.6%。Nantahala Capital Management LLC 目前拥有 995,000 股该公司的股票，价值 4,965,000 美元，此前在上个季度又购买了 95,000 股。美国银行（Bank of America Corp DE）在第二季度将其在 Avalo Therapeutics 的持股增加了 7,066.8%。美国银行（Bank of America Corp DE）目前拥有 406,571 股该公司的股票，价值 2,029,000 美元，此前在上个季度又购买了 400,898 股。Boothbay Fund Management LLC 在第二季度获得了 Avalo Therapeutics 的新股份，价值 56,000 美元。最后，Aberdeen Group plc 在第三季度获得了 Avalo Therapeutics 的新股份，价值 925,000 美元。目前，87.06% 的股票由机构投资者和对冲基金持有。</p>
<h2>Avalo Therapeutics 价格表现</h2>
<p>该公司的 50 日简单移动平均线为 15.47 美元，200 日简单移动平均线为 16.29 美元。该股票的市值为 6.032 亿美元，市盈率为 -3.93，贝塔值为 0.78。</p>
<p>Avalo Therapeutics（NASDAQ:AVTX - 获取免费报告）最近于 3 月 23 日发布了季度财报。该公司报告每股收益（EPS）为 -0.37 美元，超出市场共识预期的 -1.54 美元，超出幅度为 1.17 美元。该公司在本季度的收入为 6 万美元，而分析师预期为 -21 万美元。研究分析师预计 Avalo Therapeutics, Inc. 在本年度的每股收益将为 -3.38 美元。</p>
<h2>Avalo Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Avalo Therapeutics 是一家临床阶段的生物技术公司，专注于心代谢、纤维化和炎症疾病的新疗法的发现、开发和商业化。该公司的专有药物设计平台能够创造具有优化药代动力学特征的长效前药，旨在提高疗效、安全性和患者依从性。通过利用这项技术，Avalo 旨在解决现有治疗方法未能满足的疾病进展的关键驱动因素。</p>
<p>其主要项目包括 AVTX-002，这是一种首创的前药候选药物，旨在抑制血管紧张素原以治疗高血压及相关心血管疾病，以及 AVTX-006，这是一种早期候选药物，针对与纤维化和代谢功能障碍相关的通路。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Avalo Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Avalo Therapeutics 吗？</h2>
<p>在你考虑 Avalo Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Avalo Therapeutics 并不在名单上。</p>
<p>虽然 Avalo Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

AVTX

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

IBBQ

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

<p>Avalo Therapeutics (NASDAQ:AVTX) 在 Citizens JMP 将其目标价从 52 美元上调至 62 美元后，交易量显著增加，交易量上升了 85%，达到约 170 万股。该股票收盘价为 22.55 美元，较前一日的 21.81 美元上涨。分析师普遍对该股票给予积极评价，几次升级是在积极的试验结果和 3.75 亿美元的公开募股之后。然而，关于稀释和内部人士抛售的担忧可能会影响短期表现</p>

<p>Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) shares saw unusually-strong trading volume on Thursday after Citizens Jmp raised their price target on the stock from $52.00 to $62.00. Citizens Jmp currently has a market outperform rating on the stock. Approximately 1,699,078 shares traded hands during mid-day trading, an increase of 85% from the previous session's volume of 916,530 shares.The stock last traded at $22.55 and had previously closed at $21.81.</p>
<div class="lb-trans"><p>Avalo Therapeutics, Inc.（纳斯达克代码：AVTX - 获取免费报告）在周四的交易中，股价出现异常强劲的交易量，此前 Citizens Jmp 将其目标股价从 52.00 美元上调至 62.00 美元。Citizens Jmp 目前对该股票的评级为市场表现优于大盘。在午盘交易中，约有 1,699,078 股成交，较前一交易日的 916,530 股交易量增加了 85%。该股最后交易价格为 22.55 美元，之前收盘价为 21.81 美元。</p>
</div><p>Get <strong>Avalo Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Avalo Therapeutics</strong> 的提醒：</p>
</div><p>Other analysts have also issued reports about the company. Guggenheim began coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a &#34;buy&#34; rating and a $50.00 price objective for the company. HC Wainwright lifted their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, March 25th. Citigroup reaffirmed an &#34;outperform&#34; rating on shares of Avalo Therapeutics in a report on Wednesday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Finally, Wedbush boosted their target price on Avalo Therapeutics from $29.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $48.14.</p>
<div class="lb-trans"><p>其他分析师也对该公司发布了报告。Guggenheim 在 2 月 2 日的研究报告中开始覆盖 Avalo Therapeutics。他们给予该公司 “买入” 评级，目标价为 50.00 美元。HC Wainwright 在 3 月 25 日的报告中将 Avalo Therapeutics 的目标价从 25.00 美元上调至 40.00 美元，并给予该股 “买入” 评级。花旗集团在周三的报告中重申了对 Avalo Therapeutics 的 “优于大盘” 评级。Weiss Ratings 在 4 月 8 日的研究报告中重申了对 Avalo Therapeutics 的 “卖出（d-）” 评级。最后，Wedbush 在周三的研究报告中将 Avalo Therapeutics 的目标价从 29.00 美元上调至 40.00 美元，并给予该股 “优于大盘” 评级。一位投资分析师对该股给予了强烈买入评级，九位给予了买入评级，一位对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 48.14 美元。</p>
</div><p><strong>Check Out Our Latest Report on Avalo Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Avalo Therapeutics 的最新报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, CFO Christopher Ryan Sullivan sold 8,458 shares of the company's stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares of the company's stock, valued at approximately $116,239.20. This represents a 48.78% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider directly owned 3,622 shares of the company's stock, valued at approximately $58,495.30. This trade represents a 87.56% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 63,015 shares of company stock valued at $987,326. Company insiders own 4.46% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Christopher Ryan Sullivan 在 4 月 29 日的交易中出售了 8,458 股公司的股票。股票以平均价格 13.09 美元出售，总价值为 110,715.22 美元。交易完成后，首席财务官直接持有 8,880 股公司的股票，价值约为 116,239.20 美元。这代表其持股比例减少了 48.78%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Mittie Doyle 在 3 月 16 日的交易中出售了 25,492 股公司的股票。该股票以平均价格 16.15 美元出售，总价值为 411,695.80 美元。交易完成后，该内部人士直接持有 3,622 股公司的股票，价值约为 58,495.30 美元。这笔交易代表其持股比例减少了 87.56%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 63,015 股公司股票，价值 987,326 美元。公司内部人士持有公司股票的 4.46%。</p>
</div><h2>Key Headlines Impacting Avalo Therapeutics</h2>
<div class="lb-trans"><h2>影响 Avalo Therapeutics 的关键头条</h2>
</div><p>Here are the key news stories impacting Avalo Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Avalo Therapeutics 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Positive Phase 2 LOTUS topline results — the LOTUS trial met its primary endpoint (HiSCR75 at Week 16) at both doses and showed benefits on key secondary endpoints; Avalo said it will advance abdakibart into a registrational Phase 3 program, which materially de‑risks the program and supports higher long‑term commercial potential. Read More.</li>
<li>Positive Sentiment: Large $375M public offering priced to fund development — Avalo priced ~19.73M shares (plus pre‑funded warrants) at $17.75 to raise gross proceeds of ~$375M; management says proceeds will support abdakibart’s Phase 3 and general corporate purposes, strengthening the company’s cash runway. Read More.</li>
<li>Positive Sentiment: Analyst upgrades and higher targets — several firms raised ratings/targets (examples: BTIG to $58, Citizens JMP to $62, Wedbush to $40), reflecting renewed bullishness post‑data and likely contributing to buying interest. Read More.</li>
<li>Neutral Sentiment: Market reaction / transaction timing — the offering is expected to close subject to customary conditions (expected May 7), and the underwriters have a 30‑day option to buy additional shares; near‑term trading will reflect both the data and final closing details. Read More.</li>
<li>Negative Sentiment: Dilution and potential near‑term selling pressure — the sizable equity raise will dilute existing shareholders and could cap the stock until proceeds are deployed and Phase 3 milestones are achieved. Read More.</li>
<li>Negative Sentiment: Signatures of hedging / insider activity — reports show unusually large put option activity and recent insider sales (multiple officers selling shares), which investors may interpret as short‑term hedging or tax/liquidity sales and a cautionary indicator for near‑term volatility.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：积极的第二阶段 LOTUS 顶线结果——LOTUS 试验在两个剂量下均达到了主要终点（第 16 周的 HiSCR75），并在关键次要终点上显示出益处；Avalo 表示将推进 abdakibart 进入注册性第三阶段项目，这大大降低了项目风险，并支持更高的长期商业潜力。阅读更多。</li>
<li>积极情绪：大型 3.75 亿美元的公开发行定价以资助开发——Avalo 以 17.75 美元的价格定价约 1973 万股（加上预先融资的认股权证），以筹集约 3.75 亿美元的总收益；管理层表示收益将支持 abdakibart 的第三阶段和一般公司用途，增强公司的现金流。阅读更多。</li>
<li>积极情绪：分析师升级和更高目标——几家公司提高了评级/目标（例如：BTIG 至 58 美元，Citizens JMP 至 62 美元，Wedbush 至 40 美元），反映出数据发布后的乐观情绪，并可能促进购买兴趣。阅读更多。</li>
<li>中性情绪：市场反应/交易时机——该发行预计将在符合惯例条件的情况下完成（预计在 5 月 7 日），承销商有 30 天的选择权购买额外股票；短期交易将反映数据和最终关闭细节。阅读更多。</li>
<li>消极情绪：稀释和潜在的短期卖压——大规模的股权融资将稀释现有股东的股份，并可能限制股票价格，直到收益被使用和第三阶段里程碑达成。阅读更多。</li>
<li>消极情绪：对冲/内部人士活动的迹象——报告显示异常大的看跌期权活动和最近的内部人士出售（多位高管出售股票），投资者可能将其解读为短期对冲或税务/流动性出售，并作为短期波动的警示指标。</li>
</ul>
</div><h2>Institutional Investors Weigh In On Avalo Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Avalo Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company's stock valued at $552,000 after purchasing an additional 2,648 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in Avalo Therapeutics by 10.6% during the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company's stock valued at $4,965,000 after purchasing an additional 95,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in Avalo Therapeutics by 7,066.8% during the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company's stock valued at $2,029,000 after purchasing an additional 400,898 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics during the 2nd quarter valued at $56,000. Finally, Aberdeen Group plc acquired a new stake in Avalo Therapeutics during the 3rd quarter valued at $925,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近买卖了该公司的股票。Geode Capital Management LLC 在第二季度将其在 Avalo Therapeutics 的持股增加了 2.5%。Geode Capital Management LLC 目前拥有 110,460 股该公司的股票，价值 552,000 美元，此前在上个季度又购买了 2,648 股。Nantahala Capital Management LLC 在第二季度将其在 Avalo Therapeutics 的持股增加了 10.6%。Nantahala Capital Management LLC 目前拥有 995,000 股该公司的股票，价值 4,965,000 美元，此前在上个季度又购买了 95,000 股。美国银行（Bank of America Corp DE）在第二季度将其在 Avalo Therapeutics 的持股增加了 7,066.8%。美国银行（Bank of America Corp DE）目前拥有 406,571 股该公司的股票，价值 2,029,000 美元，此前在上个季度又购买了 400,898 股。Boothbay Fund Management LLC 在第二季度获得了 Avalo Therapeutics 的新股份，价值 56,000 美元。最后，Aberdeen Group plc 在第三季度获得了 Avalo Therapeutics 的新股份，价值 925,000 美元。目前，87.06% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Avalo Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 价格表现</h2>
</div><p>The company's 50-day simple moving average is $15.47 and its 200-day simple moving average is $16.29. The stock has a market capitalization of $603.20 million, a price-to-earnings ratio of -3.93 and a beta of 0.78.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 15.47 美元，200 日简单移动平均线为 16.29 美元。该股票的市值为 6.032 亿美元，市盈率为 -3.93，贝塔值为 0.78。</p>
</div><p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. Research analysts expect that Avalo Therapeutics, Inc. will post -3.38 earnings per share for the current year.</p>
<div class="lb-trans"><p>Avalo Therapeutics（NASDAQ:AVTX - 获取免费报告）最近于 3 月 23 日发布了季度财报。该公司报告每股收益（EPS）为 -0.37 美元，超出市场共识预期的 -1.54 美元，超出幅度为 1.17 美元。该公司在本季度的收入为 6 万美元，而分析师预期为 -21 万美元。研究分析师预计 Avalo Therapeutics, Inc. 在本年度的每股收益将为 -3.38 美元。</p>
</div><h2>Avalo Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.</p>
<div class="lb-trans"><p>Avalo Therapeutics 是一家临床阶段的生物技术公司，专注于心代谢、纤维化和炎症疾病的新疗法的发现、开发和商业化。该公司的专有药物设计平台能够创造具有优化药代动力学特征的长效前药，旨在提高疗效、安全性和患者依从性。通过利用这项技术，Avalo 旨在解决现有治疗方法未能满足的疾病进展的关键驱动因素。</p>
</div><p>Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.</p>
<div class="lb-trans"><p>其主要项目包括 AVTX-002，这是一种首创的前药候选药物，旨在抑制血管紧张素原以治疗高血压及相关心血管疾病，以及 AVTX-006，这是一种早期候选药物，针对与纤维化和代谢功能障碍相关的通路。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Avalo Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Avalo Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Avalo Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Avalo Therapeutics 吗？</h2>
</div><p>Before you consider Avalo Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Avalo Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Avalo Therapeutics 并不在名单上。</p>
</div><p>While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Avalo Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Avalo Therapeutics (NASDAQ:AVTX) Sees Large Volume Increase Following Analyst Upgrade

Market Beat

Avalo Therapeutics

Invesco Nasdaq Biotechnology ETF

Avalo Therapeutics（纳斯达克股票代码：AVTX）在分析师上调评级后交易量大幅增加